AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$AORT

Artivion outlines 2026 revenue of $484M to $492M while preparing January 2027 NEXUS launch (NYSE:AORT)

Artivion (AORT) reported 9% revenue growth and 8% adjusted EBITDA decline in Q3 2026. The company projects 2026 revenue between $484M and $492M, with the NEXUS launch planned for January 2027.

Original reporting
seekingalpha.com
Published Nov 6, 2026, 1:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 1:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AORT
Bearish
high confidence
Mentioned
$AORT
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$AORTBearishMed
01

Why it matters

The disclosed revenue range provides a concrete target for analysts and investors, influencing valuation models and short‑term price action.

02

Market read

Guidance will be incorporated into equity pricing and may affect sector sentiment.

03

What to watch

Potential upside from the upcoming NEXUS launch if it gains regulatory clearance early.

Relevance 7/10Novelty 7/10Timing: guidance release day

Background

Artivion is a medical‑device company focused on cardiac and vascular therapies. The NEXUS platform is its next‑generation product slated for early 2027.

Company-level read

Ticker impact

$AORTBearishHigh confidence
Context

Artivion disclosed its 2026 revenue guidance of $484M‑$492M and a planned January 2027 NEXUS launch.

Expected impact

potential modest downside as investors compare guidance to prior expectations

Evidence & confidence

Revenue guidance is new information that will be priced in; the range is modest and may not meet growth expectations.

Market effects

Sector

Sets a benchmark for the cardiac device sector's revenue outlook in 2026.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact beyond sector peers.

Counterpoint

What could challenge this read

If the market expects higher growth, the guidance could trigger a sell‑off.

Key entities

  • Company
    Artivion, Inc.

    Medical‑device manufacturer reporting 2026 guidance.

Read at source← All news

StoryArtivion posts Q3 loss, narrows 2026 revenue outlook and confirms NEXUS launch

Also covered by

3 outlets

Related articles

$AORTMedAI 8/10

Artivion Inc (AORT) (Q3 2026) Earnings Call Highlights: Stent Graft Momentum and Nexus

Artivion Inc. reported Q3 2026 earnings, highlighting a gross margin decline to 61.4% due to mix, ramp costs, and charges. CEO Pat Mackin expects a gradual Nexus U.S. launch in 2027. Onyx growth slowed to 13%, with mid-teens full-year growth expected. The company aims to reduce leverage through EBITDA growth, with free cash flow positive in 2027. Core stent graft growth dipped below mid-teens, but is seen as a solid double-digit business.

finance.yahoo.com
$AORTHighAI 8/10

Artivion (AORT) Q3 2026 Earnings Call Transcript

Artivion (AORT) reported Q3 2026 revenue of $123.8M, up 9% YoY. Stent graft revenues grew 12%, On-X grew 13%, while tissue processing and BioGlue saw slight declines. Adjusted EBITDA decreased 8% to $22.5M. The company expects U.S. commercial launch of NEXUS in early 2027 and FDA approval for ARCEVO LSA in 2029, unlocking an $80M opportunity. Gross margins fell to 61.4% due to mix and manufacturing investments. Free cash flow was negative $17.6M.

finance.yahoo.com
$AORTMed

Artivion: Q3 Earnings Snapshot

Artivion, Inc. (AORT) reported a Q3 loss of $7.9 million, down from a profit last year. Adjusted EPS was 8 cents. Revenue was $123.8 million. The company expects Q4 revenue between $484M and $492M. Shares have fallen 45% YTD and 46% over 12 months.

finance.yahoo.com
$AORTMed

Artivion Reports Third Quarter 2026 Financial Results

ARTIVION, INC. (AORT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston Executive Vice President, Phone: 332-895-3222 Chief Operating Officer & investors@artivion.com Chief Financial Officer Phone: 770-419-3355 Artivion Reports Third Quarter 2026 F

SEC EDGAR 8-K
$AORTMed

Artivion Reports Third Quarter 2026 Financial Results

Artivion reported Q3 2026 revenue of $123.8M, up 9% YoY, with a net loss of $7.9M. Adjusted EBITDA declined 8% to $22.5M. CEO Pat Mackin highlighted growth in On-X and stent grafts, and progress in product launches. The company narrowed its 2026 revenue outlook to $484M-$492M, with adjusted EBITDA expected between $93M-$98M.

prnewswire.com
$AORTHigh

Why is Artivion stock rallying today?

Artivion (AORT) stock rose 4.7% after Jefferies initiated coverage with a Buy rating and $31 price target, citing near-term product catalysts and growth potential. The firm expects 39% upside from the prior close, highlighting product launches and margin accretion. Artivion's Q3 2026 earnings report is due soon, adding to near-term interest.

investing.com